Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2021
Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders
Vankawala J, Naples G, Avila-Quintero VJ, Ramírez KL, Flores JM, Bloch MH, Dwyer JB. Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders. Frontiers In Psychiatry 2021, 12: 549080. PMID: 33841195, PMCID: PMC8024485, DOI: 10.3389/fpsyt.2021.549080.Peer-Reviewed Original ResearchTreatment-resistant depressionSub-anesthetic dosesPost-traumatic stress disorderKetamine treatmentBlood pressureObsessive-compulsive disorderKetamine dosesHemodynamic parametersPsychiatric disordersPsychiatric populationsAverage heart rate increaseKetamine/esketamineStratified subgroup analysisKetamine-induced changesPotential cardiovascular riskHeart rate increaseAdult psychiatric populationSignificant increaseAdult age groupsSub-anesthetic ketamineEsketamine treatmentCardiovascular riskKetamine infusionHemodynamic changesSBP increase
2013
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder
Niciu MJ, Grunschel B, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. Journal Of Psychopharmacology 2013, 27: 651-654. PMID: 23676198, DOI: 10.1177/0269881113486718.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAntidepressant effectsPsychiatric comorbidityComorbid depressionNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistTreatment-refractory obsessive-compulsive disorderAcute antidepressant effectsTreatment-resistant unipolarOpen-label trialSevere respiratory depressionAdverse neuropsychiatric effectsComorbid psychiatric disordersMinimal depressive symptomsOff-label useMajor depressive disorderStart of infusionRespiratory depressionIntravenous ketamineNeuropsychiatric effectsKetamine infusionBipolar depressionReceptor antagonistDepressive disorderSedative effectsRelationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18: 1199-1204. PMID: 23337947, PMCID: PMC3646075, DOI: 10.1038/mp.2012.194.Peer-Reviewed Original ResearchConceptsFunctional connectivityNegative symptomsGamma-aminobutyric acid (GABA) neuronsNMDA receptor antagonist ketamineAspartate glutamate receptor antagonistContinuous ketamine infusionGlutamate receptor antagonistsNMDA-R antagonistsCortical functional connectivityNMDA-R antagonist ketamineSchizophrenia-like symptomsHealthy human subjectsNegative Syndrome ScaleBrain functional connectivityPrimary samplesRegion-specific mannerFunctional magnetic resonanceKetamine infusionReceptor antagonistPathological increaseSyndrome ScaleSymptomsPreclinical researchKetamineBrain oscillations
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion